Abstract
This article provides a review of the role of aliskiren, a direct renin inhibitor, in pediatric hypertension and kidney diseases. Among the many mechanisms involved in regulating blood pressure, the renin–angiotensin–aldosterone system (RAAS) plays a major role. Additionally, the RAAS has been identified as a contributing factor to cardiovascular and renal diseases for more than three decades. The potential benefits of inhibiting the RAAS by aliskiren alone or in combination with other RAAS blockers (ACEIs, ARBs) seem to be theoretically promising. However, caution should be exercised in treating children, especially in those with significant chronic kidney disease until there is more evidence regarding the safety and efficacy of this new drug in the pediatric population from ongoing clinical trials.
Original language | English (US) |
---|---|
Pages (from-to) | 2105-2111 |
Number of pages | 7 |
Journal | Pediatric Nephrology |
Volume | 29 |
Issue number | 11 |
DOIs | |
State | Published - Nov 2014 |
Externally published | Yes |
Keywords
- Aliskiren
- Angiotensin
- Blood pressure
- Hyperkalemia
- Hypertension
- Renin
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Nephrology